Sembragiline

Research use only, not for human use.

Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM.

Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A; displays no affinity for more than 100 different receptors, enzymes and ion channels; protects against neuronal loss and reduces both ROS formation and reactive astrogliosis in transgenic animal model conditionally overexpressing MAO-B in astroglia, exhibits potential for treatment of Alzheimer's disease (AD) and other neurodegenerative disorders.Alzheimer Disease Phase 2 Clinical.

——

——

RO4602522 | RG1577 | EVT 302

Metabolic Enzyme/Protease

MAO

MAO

Neurological Disease

Alzheimer Disease

676479-06-4

342.37

C19H19FN2O3

>98% (HPLC)

——

CC(N[C@@H](C1)CN(C2CCC(OCC3=CC=CC(F)=C3)CC2)C1=O)=O

(3S)-N-{1-[4-(3-fluorobenzyloxy)-phenyl]-5-oxo-pyrrolidin-3-yl} acetamide

(-20℃)

With Ice Pack

≥ 2 years